23.92EURMkt Cap: —P/E: 3.23Last update: 2026-05-21
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value-1.43B EUR
Revenue (TTM)1.04B EUR
Gross Profit1.08B EUR
Net Income (TTM)320.88M EUR
Revenue/Share15.84 EUR
Last Price23.92 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINBE0003818359
Valuation
P/E (Trailing)3.23
P/E (Forward)-6.70
PEG—
EV/EBITDA-2.15
EV/Revenue-1.37
P/S—
P/B—
EPS (TTM)7.41
EPS (Forward)-3.57
52W Range
23.2489% of range24.00
52W High24.00 EUR
52W Low23.24 EUR
Profitability
Gross Margin97.33%
Oper. Margin-982.92%
EBITDA Margin63.52%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-91.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-257.46M EUR
CapEx (TTM)13.86M EUR
FCF Margin20.21%
FCF Yield—
Net Debt-2.98B EUR
Net Debt/EBITDA-4.49
Balance Sheet
Debt/Equity0.00
Current Ratio30.48
Quick Ratio30.23
Book Value/Sh—
Cash/Share45.26 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.4 (Hold)
Target (Mean)30.15 EUR
Target Range19.00 EUR – 44.80 EUR
# Analysts8
Ownership
Shares Out.—
Float44.54M
Insiders25.36%
Institutions30.56%
Technical
SMA 5025.12 (-4.8%)
SMA 20027.29 (-12.4%)
Beta0.12
S&P 52W Chg27.23%
Avg Vol (30d)66.27K
Avg Vol (10d)80.99K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—